"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 4 | 4 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 6 | 6 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 7 | 9 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 5 | 7 |
| 2005 | 3 | 3 | 6 |
| 2006 | 1 | 3 | 4 |
| 2007 | 4 | 6 | 10 |
| 2008 | 4 | 6 | 10 |
| 2009 | 2 | 9 | 11 |
| 2010 | 7 | 6 | 13 |
| 2011 | 0 | 10 | 10 |
| 2012 | 5 | 3 | 8 |
| 2013 | 7 | 8 | 15 |
| 2014 | 4 | 6 | 10 |
| 2015 | 7 | 9 | 16 |
| 2016 | 8 | 4 | 12 |
| 2017 | 7 | 4 | 11 |
| 2018 | 2 | 10 | 12 |
| 2019 | 4 | 14 | 18 |
| 2020 | 3 | 15 | 18 |
| 2021 | 3 | 9 | 12 |
| 2022 | 1 | 16 | 17 |
| 2023 | 0 | 13 | 13 |
| 2024 | 2 | 9 | 11 |
| 2025 | 1 | 4 | 5 |
| 2026 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers. Nat Commun. 2026 Jan 03; 17(1):1193.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894.
-
Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus Nephritis. Arthritis Rheumatol. 2024 Mar; 76(3):469-478.
-
Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
-
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma. Pediatr Hematol Oncol. 2023 May; 40(4):422-428.
-
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 02 01; 12(2):25.
-
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15; 128(2):317-325.
-
Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Br J Haematol. 2021 07; 194(1):145-157.